Category: News & Events

Multi-Omics Exploration of Risk Factors and Pathways Linking Respiratory Conditions and Abdominal Aortic Aneurysm

Multi-Omics Exploration of Risk Factors and Pathways Linking Respiratory Conditions and Abdominal Aortic AneurysmAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. This editorial highlights a landmark study that applies an integrative multi-omics framework to uncover a causal connection between chronic obstructive pulmonary disease (COPD) and abdominal aortic aneurysm (AAA). Through the combined use of bidirectional Mendelian randomization (MR), tissue-specific expression quantitative trait loci (eQTL) analysis, single-cell RNA sequencing (scRNA-seq), and phenome-wide association studies (PheWAS), the study provides robust genetic and molecular evidence linking the two diseases.

A key discovery is the identification of 48 genes associated with both conditions, including KIF3A, a gene found to inhibit disease activity in both COPD and AAA. The integration of scRNA-seq data allowed localization of relevant genes—such as PLTP, RIF1, and IFI27L2—to immune and stromal cells, providing insights into tissue-specific mechanisms of pathogenesis.

Read more: https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0019

(more…)

Loading

Genetic and Molecular Relationships Between Chronic Obstructive Pulmonary Disease and Abdominal Aortic Aneurysm: Insights from a Multi-Omics Approach

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Chronic obstructive pulmonary disease (COPD) and abdominal aortic aneurysm (AAA) are both severe conditions with complex etiologies and substantial comorbidities. Previous studies have suggested a potential relationship between these diseases, but the underlying genetic and molecular mechanisms remain unclear.

Bidirectional two-sample Mendelian randomization (MR) was used to investigate the causal relationship between COPD and AAA. Expression quantitative trait loci (eQTL) analysis was performed with GTEx V8 summary statistics for aortic and lung tissues. Single-cell sequencing data from GEO datasets were analyzed to identify differentially expressed genes. Finally, a phenome-wide association study (PheWAS) was conducted to explore the broader implications of identified pathogenic genes. (more…)

Loading

Nomogram-Based Prediction of Mortality after Cardiac Resynchronization Therapy in Patients with Heart Failure

Nomogram-Based Prediction of Mortality after Cardiac Resynchronization Therapy in Patients with Heart FailureAnnouncing a new article publication for Cardiovascular Innovations and Applications journal.  Heart failure (HF) with reduced ejection fraction (HFrEF; LVEF ≤ 35%) affects more than 64 million people globally. The 5-year all-cause mortality exceeds 40% among this population. CRT is a cornerstone treatment for patients with HFrEF with left bundle branch block, prolonged QRS complex duration (ventricular depolarization interval ≥ 150 ms on an electrocardiogram), and New York Heart Association (NYHA) class II–IV symptoms despite optimal medical therapy. However, many patients remain at high risk of mortality post-CRT, particularly those who develop new-onset atrial fibrillation (NOAF), which can disrupt resynchronization and worsen prognosis. Existing prognostic models often do not include NOAF and may lack precision.

(more…)

Loading

Announcing the Cardiovascular Innovations and Applications (CVIA) 2024 Impact Factor is 1.4

The Co-Editors-in-Chief of Cardiovascular Innovations and Applications (CVIA), Jamie B. Conti, University of Florida, Gainesville, FL, USA, Jianzeng Dong, Beijing Anzhen Hospital, Capital Medical University, Beijing, China and Jun Pu, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, are pleased to announce that the 2024 Journal Impact Factor (JIF) for CVIA is 1.4.

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Articles of interest include:

Machine Learning Methods in Real-World Studies of Cardiovascular Disease

The Evolving Role of Transcatheter Tricuspid Valve Edge-to-Edge Repair in Tricuspid Regurgitation

Overview of Postural Orthostatic Tachycardia Syndrome (POTS) for General Cardiologists

Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation

Angiography-Based Computational Modeling for In Vivo Assessment of Endothelial Dynamic Strain in Coronary Arteries with De Novo Lesions: Comparison of Treatment Effects of Drug-Coated Balloons Between Small and Large Arteries

Feasibility of an Integrated Digital and Pharmacological Approach Targeting Blood Lipids in Atherosclerotic Cardiovascular Disease Management

Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients ≥75 Years of Age with Acute Coronary Syndrome

Heart Failure Guideline Directed Medical Therapy: Which One and When?

Overview of Injectable Hydrogels for the Treatment of Myocardial Infarction

Surgical Treatment of Aortic Annulus Damaged by Infective Endocarditis: A Single-Center Experience

Loading

Comparative Analysis of Surgical Outcomes in Cardiac Myxoma Resection: Sternotomy Versus Right Mini-Thoracotomy

minithoracotomyAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. Despite increasing use of minimally invasive techniques, limited literature has described minithoracotomy for removal of left atrial masses, such as myxomas. This article addresses this gap by analyzing more than a decade of experience at the Cardiovascular Department, Maria Cecilia Hospital, Cotignola, Italy.

Between January 2010 and May 2024, 116 patients underwent either right minithoracotomy or median sternotomy for left atrial myxoma resection. This retrospective study included 96 patients and excluded 20 patients receiving additional procedures. No prior sample size calculation was performed. (more…)

Loading

Type 2 Inflammation: A Potential Clinical Link Between Asthma and Cardiovascular Diseases

Type 2 Inflammation: A Potential Clinical Link Between Asthma and Cardiovascular DiseasesAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. Asthma and cardiovascular diseases (CVDs) are intricately linked, because of their widespread prevalence and shared pathophysiological processes. People who have experienced overlapping asthma exacerbation, persistent asthma, or asthma-chronic obstructive pulmonary disease (COPD) face elevated CVD morbidity and mortality risks. These risks are exacerbated in cases of type 2 asthma, a common phenotype of severe asthma leading to accelerated CVD progression. However, type 2 inflammation also exhibits protective effects against CVDs. This review explores the dual role of type 2 inflammation in CVDs, emphasizing its detrimental effects (e.g., exacerbating atherosclerosis) and protective mechanisms (e.g., release of atheroprotective cytokines such as IL-5 and IL-13). Furthermore, it examines the therapeutic potential of anti-asthma medications targeting type 2 inflammation to mitigate CVD progression.

(more…)

Loading

Inhibition of Cyclic GMP-AMP Synthase Ameliorates Cardiac Dysfunction in Rats After Cardiac Arrest

Cyclic GMP-AMP synthaseAnnouncing a new article publication for Cardiovascular Innovations and Applications journal. Cardiac dysfunction is a prevalent and serious complication after cardiac arrest (CA), yet limited therapeutic interventions are available. Cyclic GMP-AMP synthase (cGAS), a critical mediator of innate immune responses, has recently been identified as a potential contributor to cardiac dysfunction. This study was aimed at investigating the role of cGAS in post-CA cardiac dysfunction.

In vivo, in rats with ventricular fibrillation (VF)-induced CA, a selective cGAS inhibitor (RU.521) was used to specifically inhibit cGAS activity, thereby blocking its downstream signaling pathway. In vitro, hypoxia and reoxygenation (H/R) were used to stimulate H9C2 cardiomyocytes, and a specific siRNA targeting cGAS was applied to knock down cGAS expression. (more…)

Loading

Roles of Mitochondrial Quality Control in the Pathogenesis of Atherosclerosis

Mitochondrial Quality Control (MQC)Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Mitochondrial quality control (MQC) mechanisms – including biogenesis, dynamics, mitophagy, proteostasis, the unfolded protein response, and mitochondrial-derived vesicles – play critical roles in the development of atherosclerosis. Dysregulation of these processes can lead to mitochondrial dysfunction, and subsequently the initiation of a pathological cascade characterized by oxidative stress, chronic inflammation, and the accumulation of lipids within arterial walls. Specifically, ROS overproduction and redox state imbalance are key molecular aspects that exacerbate mitochondrial damage, and create a self-perpetuating cycle of cellular injury and disease progression.

Emerging therapeutic strategies targeting the modulation of MQC have promise in attenuating atherosclerotic progression by restoring mitochondrial biogenesis, restoring the balance of fusion and fission dynamics, enhancing the clearance of damaged mitochondria, and improving protein homeostasis. (more…)

Loading

Current Understanding and Evidence Regarding Qiliqiangxin (QLQX) in Heart Failure Treatment: From Basic to Clinical Research

Illustration of Qiliqiangxin (QLQX) mechanisms and clinical effects in heart failure treatment, from basic research to clinical application.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Qiliqiangxin (QLQX), a traditional Chinese medicine (TCM) formulation, has shown therapeutic potential in heart failure (HF) through its multifaceted mechanisms. This review article synthesizes preclinical and clinical evidence, highlighting the ability of QLQX to modulate cardiac remodeling, inflammation, fibrosis, and neurohormonal activation. Preclinical studies have revealed that the bioactive components of QLQX target peroxisome proliferator-activated receptor γ, mitochondrial metabolism, and calcium transport. Clinically, QLQX capsule decreases N-terminal pro B-type natriuretic peptide levels and improves functional outcomes in chronic HF. (more…)

Loading